Secondly, although genetic variations linked to illness risk—such as APOE4 in AD or LRRK2 in PD—have been identified, the translation of these discoveries into viable treatment targets has progressed slowly due to an inadequate comprehension of their functional implications. Here, APOE is linked to Parkinson disease.